Inclusion Criteria:  Histologically confirmed HCC, which is unresectable, recurrent and/or metastatic. GPC3-positive expression in HCC tumor cells by immunohistochemistry (IHC). Must have failed or not tolerated at least two (2) different anti-HCC systemic agents. Life expectancy of at least 4 months per Principal Investigator's opinion. Karnofsky Performance Scale ≥ 70. Measurable disease by RECIST v.1.1. Previously treated lesions are allowed as long as there is a new confirmed measurable component. Child-Pugh score A6 or better. Adequate organ function.  Exclusion Criteria:  Clinically significant pre-existing illness (e.g., heart failure) Uncontrolled systemic bacterial, fungal, or viral infection Active malignancy other than HCC, with the exception of cholangiocarcinoma (CCA) without any organ involvement and with an expected survival greater than or equal to 3 years without any treatment (exception: hormone/androgen- deprivation therapy) Active autoimmune disease requiring therapy Compromised circulation in portal vein, hepatic vein, or vena cava due to obstruction History of organ transplant Advanced HCC involving greater than half (50%) of the liver